136 related articles for article (PubMed ID: 34551905)
21. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
22. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
23. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
24. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
25. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Liu YN; Su KY; Chang YL; Wu CT; Liao BC; Hsu CC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Oncologist; 2020 Aug; 25(8):702-711. PubMed ID: 32386255
[TBL] [Abstract][Full Text] [Related]
26. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
27. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
28. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
[TBL] [Abstract][Full Text] [Related]
29. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
[TBL] [Abstract][Full Text] [Related]
30. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
32. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
[TBL] [Abstract][Full Text] [Related]
33. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
[TBL] [Abstract][Full Text] [Related]
34. Crizotinib targets in glioblastoma stem cells.
Junca A; Villalva C; Tachon G; Rivet P; Cortes U; Guilloteau K; Balbous A; Godet J; Wager M; Karayan-Tapon L
Cancer Med; 2017 Nov; 6(11):2625-2634. PubMed ID: 28960893
[TBL] [Abstract][Full Text] [Related]
35. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases.
Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF
Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781
[TBL] [Abstract][Full Text] [Related]
36. Pediatric Non-Myofibroblastic Primitive Spindle Cell Tumors with
Rakheja D; Park JY; Fernandes NJ; Watt TC; Laetsch TW; Collins RRJ
Int J Surg Pathol; 2022 Sep; 30(6):706-715. PubMed ID: 35164578
[TBL] [Abstract][Full Text] [Related]
37. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
40. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]